This approach identified for the first time 3 novel lead compounds that competitively inhibit Stat3 binding to its pY-peptide ligand, that are selective for Stat3 vs. Stat1 and that also induce apoptosis preferentially of breast cancer cells lines with constitutively activated Stat3. The gene discussed is STAT3; the disease is breast carcinoma.